Invasive Breast Cancer
81
13
25
29
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
15 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.4%
6 terminated out of 81 trials
82.9%
-3.6% vs benchmark
9%
7 trials in Phase 3/4
52%
15 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (81)
Genetic Testing for All Breast Cancer Patients (GET FACTS)
Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)
Onvansertib + Paclitaxel In TNBC
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Olaparib In Metastatic Breast Cancer
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
Prospective Breast Cancer Biospecimen Collection
Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Sacituzumab Govitecan In TNBC